Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study

• Published in: Medicine and pharmacy reports 2023-10, Vol.96 (4), p.368-383
• Main Authors: Timis, Teodora-Larisa, Beni, Lehel, Florian, Ioan-Alexandru, Orăsan, Meda, Orăsan, Remus Ioan
• Format: Article
• Language: English
• Subjects: Original Research: Metabolic Diseases
• ISSN: 2602-0807; 2668-0572
• DOI: 10.15386/mpr-2631

Background. As a chronic inflammatory disease, psoriasis affects not only the skin but also the metabolic profile of the patients. Biologic therapies, including tumor necrosis alpha (TNF-a) inhibitors and interleukin (IL)-12/23 and IL-17 antagonists, have proven effective in the reduction of psoriasis severity; however their impact on the metabolic and chronic inflammatory profiles of the patients remains incompletely elucidated. Methods. We performed a longitudinal case-control study on 106 psoriasis patients and an equal number of controls without the disease, as well as a prospective study on the patient group with the end point being 6 months of biologic therapy. Patients received either ixekizumab, secukinumab, guselkumab, certolizumab, ustekinumab, risankizumab, or adalimumab. Abdominal circumference, serum fasting glucose, triglycerides (TG), high-density lipoproteins (HDL), erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) were measured for both patients and controls, with an additional measurement for patients after 6 months. Results. At baseline, the number of psoriasis patients suffering from obesity, metabolic syndrome, and chronic inflammation significantly outnumbered controls (p